Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jan 27, 2025
- Pharmaceuticals
- R&D
Roche Announces New Results from EMBARK Study of Elevidys in Duchenne Muscular Dystrophy
TOKYO, January 27, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on January 27 (local time) regarding new results from EMBARK study of delandistrogene moxeparvovec, a gene therapy product under development (development code: SRP-9001, overseas product name: Elevidys) for Duchenne muscular dystrophy (DMD).
Please refer to the link below for details of the press release:
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
https://www.roche.com/media/releases/med-cor-2025-01-27
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp